Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina (STELLA).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Cilostazol (Primary)
- Indications Variant angina pectoris
- Focus Therapeutic Use
- Acronyms STELLA
- Sponsors Korea Otsuka Pharmaceutical
- 04 Sep 2013 Primary endpoint 'Angina-pectoris-event-rate' has been met according to results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
- 04 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
- 13 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.